<DOC>
	<DOCNO>NCT00958633</DOCNO>
	<brief_summary>Patients bipolar I disorder ( BD ) experience depression 3 time frequently mania , antidepressant prescribe adjunct mood stabilizer 70 % patient . However , placebo-controlled trial assess efficacy safety modern antidepressant combination mood stabilizer maintenance treatment BD . The investigator propose multicentre , randomize , double-blind clinical trial compare mood stabilizer plus antidepressant ( escitalopram bupropion XL ) mood stabilizer plus placebo maintenance treatment BD . The investigator hypothesize clinically representative patient bipolar disorder , respond acute treatment newer antidepressant medication conjunction mood stabilize medication , continue antidepressant 12 month reduce risk relapse mood episode , include depression , mania , hypomania , compare stop antidepressant 8 week .</brief_summary>
	<brief_title>Mood Stabilizer ( MS ) + Antidepressant v MS + Placebo Maintenance Bipolar Disorder .</brief_title>
	<detailed_description>Study Design : The investigator propose multicentre , randomize , double-blind , placebo-controlled trial patient BD currently experience depressive episode . The trial consist two phase : open-label acute treatment phase , double-blind maintenance treatment phase . OPEN-LABEL ACUTE TREATMENT PHASE Experimental Design Patients BD depression receive treatment antimanic medication ( ) , define : 1 ) mood stabilizer ( lithium divalproex ) , 2 ) second-generation antipsychotic ( SGA ) ( risperidone , olanzapine , quetiapine , aripiprazole , ziprasidone ) , 3 ) combination anti-manic therapy ( two mood stabilizer ; mood stabilizer plus SGA ( SGA asenapine also permit prescribed mood stabilizer ) ; mood stabilizer SGA plus lamotrigine ) , open-label escitalopram 10-30 mg/day bupropion XL 150-450 mg/day add medication ( ) 16 weeks.Patients complete least 4 week treatment achieve remission index depression maintain ≥ 2 week eligible enter double-blind study phase . The duration treatment open-label phase 4-16 week , depend time require achieve remission . DOUBLE-BLIND MAINTENANCE TREATMENT PHASE Patients remission index depression ≥ 2 week ≤ 8 week eligible take part double-blind maintenance phase . There two route enter double-blind phase : - follow completion open-label phase , - follow period clinical treatment , exceed 16 week , medication use open-label phase . Patients respond clinical treatment carbamazepine plus antidepressant may also enter double-blind phase . Experimental Design During double-blind phase , patient continue treatment anti-manic medication ( ) randomize one two treatment arm 52 week : - Patients randomize `` 8 week arm '' discontinue antidepressant treatment 8 week , recommend current clinical practice guidelines.. - Patients randomize `` 52 week arm '' continue treatment antidepressant medication 52 week , withdrawal study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>OPENLABEL ACUTE TREATMENT PHASE 1 . Diagnosed BD , current episode depress , MADRS score ≥ 20 screen baseline assessment 2 . The duration current depressive episode ≥ 2 week ≤ 52 week 3 . Taking initiate treatment antimanic medication therapeutic dose . Antimanic medication therapeutic dos : lithium , serum level 0.61.4 mEq/L ; divalproex , serum level 350700 mM ; risperidone 16 mg/day ; olanzapine 530 mg/day ; quetiapine IR XR 300900 mg/day ; aripiprazole 1030 mg/day ; ziprasidone 80160 mg/day . Combinations medication outline , combination lamotrigine 100400 mg daily , combination mood stabilizer plus asenapine 520 mg/day , also permit . 4 . If take psychoactive medication ( lorazepam ≤ 4 mg/day equivalent ) , agreeable taper discontinue period ≤ 4 week 5 . If female childbearing potential , use adequate method contraception . 6 . Aged 1870 year , inclusive 7 . Fluent English capable providing inform consent DOUBLEBLIND MAINTENANCE TREATMENT PHASE • Patients meeting follow criterion eligible include doubleblind study phase : 1 . Taking escitalopram 1030 mg/day bupropion XL 150450 mg/day , addition antimanic medication . 2 . Has adequately tolerate combination antidepressant plus mood stabilizer , currently remission ≥ 2 week ≤ 8 week 3 . If female childbearing potential , use adequate method contraception OPENLABEL ACUTE TREATMENT PHASE 1 . Has history rapid cycling , define ≥ 4 mood episode precede 12 month 2 . Has current manic , hypomanic , subsyndromal hypomanic symptom , define Young Mania Rating Scale ( YMRS ) score ≥ 8 screen baseline visit 3 . Has previously refractory treatment escitalopram bupropion XL , unable tolerate medication due intolerable side effect allergic reaction 4 . Is take monoamine oxidase inhibitor , phenelzine tranylcypromine 5 . Escitalopram contraindicate patient take pimozide ziprasidone . Patients pimozide ziprasidone participate study prescribe bupropion XL 6 . Bupropion XL contraindicate patient take preparation contain bupropion , patient active eating disorder , include anorexia nervosa bulimia nervosa ; patient seizure disorder . Patients still participate study prescribe Escitalopram 7 . Has active substance dependence , caffeine nicotine dependence , precede 3 month . Otherwise , patient comorbid substance abuse comorbid psychiatric illness eligible participate study 8 . Is high risk suicide , define score ≥ 4 suicide item MADRS , opinion investigator 9 . Has unstable medical illness , define change medication treatment past 4 week , opinion investigator 10 . Has significant abnormality electrocardiogram 11 . Is pregnant lactate DOUBLEBLIND MAINTENANCE TREATMENT PHASE 1 . Has history rapid cycling , define ≥ 4 mood episode precede 12 month 2 . Has current manic , hypomanic , subsyndromal hypomanic symptom , define YMRS score ≥ 8 screen baseline visit 3 . Has active substance dependence , caffeine nicotine dependence , precede 3 month . Otherwise , patient comorbid substance abuse comorbid psychiatric illness eligible participate study 4 . Is high risk suicide , define score ≥ 4 suicide item MADRS , opinion investigator 5 . Has unstable medical illness , define change medication treatment past 4 week , opinion investigator . 6 . Has significant abnormality electrocardiogram 7 . Is pregnant lactate 8 . Has experience episode mania , hypomania , mixed episode antidepressant treatment acute depression , define YMRS score ≥ 16 openlabel study visit , opinion study psychiatrist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bipolar I disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Antidepressant</keyword>
</DOC>